ClinicalTrials.Veeva

Menu

Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

P

Peking University

Status

Completed

Conditions

Advanced MDS Without Identical Sibling Donor

Treatments

Procedure: transplant with haploidentical donor

Study type

Observational

Funder types

Other

Identifiers

NCT01793675
PUPH IRB [2013] (04)

Details and patient eligibility

About

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast >5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source.

the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Enrollment

116 patients

Sex

All

Ages

2 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression
  • without identical sibling donor

Exclusion criteria

  • Contraindication to HSCT
  • Pregnancy
  • Mental illness

Trial design

116 participants in 1 patient group

haploidentical transplant
Description:
transplant with haploidentical donor
Treatment:
Procedure: transplant with haploidentical donor

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems